BR9503812A - Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto - Google Patents

Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto

Info

Publication number
BR9503812A
BR9503812A BR9503812A BR9503812A BR9503812A BR 9503812 A BR9503812 A BR 9503812A BR 9503812 A BR9503812 A BR 9503812A BR 9503812 A BR9503812 A BR 9503812A BR 9503812 A BR9503812 A BR 9503812A
Authority
BR
Brazil
Prior art keywords
compound
preparation
treatment
pharmaceutical composition
use method
Prior art date
Application number
BR9503812A
Other languages
English (en)
Other versions
BRPI9503812B1 (pt
Inventor
Valerie Denise Harding
Ross James Macrae
Ronald James Ogilvie
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9503812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of BR9503812A publication Critical patent/BR9503812A/pt
Publication of BRPI9503812B1 publication Critical patent/BRPI9503812B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI9503812A 1994-08-27 1995-08-25 composto e composição farmacêutica BRPI9503812B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents

Publications (2)

Publication Number Publication Date
BR9503812A true BR9503812A (pt) 1996-04-16
BRPI9503812B1 BRPI9503812B1 (pt) 2017-04-18

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9503812A BRPI9503812B1 (pt) 1994-08-27 1995-08-25 composto e composição farmacêutica

Country Status (45)

Country Link
US (2) US6110940A (pt)
EP (1) EP0776323B1 (pt)
JP (1) JP2904588B2 (pt)
KR (1) KR100228952B1 (pt)
CN (1) CN1066727C (pt)
AP (1) AP576A (pt)
AT (1) ATE163182T1 (pt)
AU (1) AU691005B2 (pt)
BG (1) BG61840B1 (pt)
BR (1) BRPI9503812B1 (pt)
CA (1) CA2198599C (pt)
CO (1) CO4410334A1 (pt)
CZ (1) CZ287693B6 (pt)
DE (1) DE69501620T2 (pt)
DK (1) DK0776323T3 (pt)
DZ (1) DZ1923A1 (pt)
EG (1) EG23822A (pt)
ES (1) ES2112650T3 (pt)
FI (1) FI113768B (pt)
GB (1) GB9417310D0 (pt)
GR (1) GR3026475T3 (pt)
HR (1) HRP950460B1 (pt)
HU (1) HU227822B1 (pt)
IL (1) IL115013A (pt)
IS (1) IS1850B (pt)
LV (1) LV11800B (pt)
MA (1) MA23650A1 (pt)
MX (1) MX9701538A (pt)
MY (1) MY113733A (pt)
NO (1) NO311297B1 (pt)
NZ (1) NZ288210A (pt)
OA (1) OA10600A (pt)
PE (1) PE41596A1 (pt)
PL (1) PL180867B1 (pt)
RO (1) RO116400B1 (pt)
RU (1) RU2159241C2 (pt)
SA (1) SA95160156B1 (pt)
SI (1) SI9520091B (pt)
SK (1) SK282922B6 (pt)
TN (1) TNSN95092A1 (pt)
TR (1) TR199501061A2 (pt)
UA (1) UA45980C2 (pt)
WO (1) WO1996006842A1 (pt)
YU (1) YU49287B (pt)
ZA (1) ZA957142B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DK0999841T3 (da) * 1997-07-03 2001-11-19 Pfizer Farmaceutiske præparater indeholdende eletriptanhemisulfat og koffein
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
EP1615635A1 (en) 2003-04-11 2006-01-18 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
RU2408368C2 (ru) * 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
WO2008137134A2 (en) * 2007-05-01 2008-11-13 Teva Pharmaceuticals Usa, Inc. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
US20080319205A1 (en) * 2007-05-29 2008-12-25 Roman Bednar Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
WO2010015692A2 (en) * 2008-08-07 2010-02-11 Biovail Laboratories International Srl Bupropion hydrobromide polymorphs
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
KR0179053B1 (ko) * 1990-10-15 1999-03-20 알렌 제이.스피겔 인돌 유도체
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
ES2143992T3 (es) * 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (pt) * 1992-03-05 1996-10-11 Pfizer
KR0179072B1 (ko) * 1992-04-07 1999-03-20 알렌 제이. 스피겔 5-ht1 작동약으로서의 인돌 유도체
KR0179074B1 (ko) * 1992-04-10 1999-03-20 알렌 제이. 스피겔 5-ht1 작용물질로서의 아실아미노인돌 유도체
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
CN1121348A (zh) * 1993-04-22 1996-04-24 辉瑞研究及发展公司 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ATE170836T1 (de) * 1993-08-31 1998-09-15 Pfizer 5-arylindolderivate

Also Published As

Publication number Publication date
EP0776323B1 (en) 1998-02-11
FI970800A0 (fi) 1997-02-26
YU49287B (sh) 2005-03-15
BRPI9503812B1 (pt) 2017-04-18
CN1066727C (zh) 2001-06-06
EG23822A (en) 2007-09-19
CZ56397A3 (cs) 1998-05-13
YU56995A (sh) 1998-07-10
MX9701538A (es) 1997-05-31
FI970800A (fi) 1997-02-26
DE69501620D1 (de) 1998-03-19
US6380226B1 (en) 2002-04-30
NO970861L (no) 1997-02-26
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
CN1155886A (zh) 1997-07-30
ES2112650T3 (es) 1998-04-01
ZA957142B (en) 1997-02-25
MA23650A1 (fr) 1996-04-01
AP576A (en) 1997-03-20
CA2198599A1 (en) 1996-03-07
PL180867B1 (pl) 2001-04-30
NO970861D0 (no) 1997-02-26
AU691005B2 (en) 1998-05-07
JPH09512283A (ja) 1997-12-09
KR100228952B1 (ko) 1999-11-01
LV11800A (lv) 1997-06-20
PE41596A1 (es) 1996-10-12
UA45980C2 (uk) 2002-05-15
SI9520091A (sl) 1998-02-28
HRP950460B1 (en) 2000-02-29
AU2735295A (en) 1996-03-22
PL318319A1 (en) 1997-06-09
ATE163182T1 (de) 1998-02-15
IL115013A0 (en) 1995-12-08
DZ1923A1 (fr) 2002-02-17
GB9417310D0 (en) 1994-10-19
IS4401A (is) 1996-12-19
GR3026475T3 (en) 1998-06-30
BG61840B1 (bg) 1998-07-31
HU227822B1 (en) 2012-03-28
JP2904588B2 (ja) 1999-06-14
SA95160156B1 (ar) 2005-05-30
EP0776323A1 (en) 1997-06-04
WO1996006842A1 (en) 1996-03-07
CO4410334A1 (es) 1997-01-09
BG101250A (en) 1997-09-30
AP9500754A0 (en) 1995-07-31
SI9520091B (sl) 2004-10-31
DK0776323T3 (da) 1998-03-30
IL115013A (en) 2000-11-21
FI113768B (fi) 2004-06-15
KR970705557A (ko) 1997-10-09
TNSN95092A1 (fr) 1996-02-06
LV11800B (en) 1997-10-20
OA10600A (en) 2000-04-06
RU2159241C2 (ru) 2000-11-20
IS1850B (is) 2003-02-07
US6110940A (en) 2000-08-29
HRP950460A2 (en) 1997-08-31
CZ287693B6 (en) 2001-01-17
SK24897A3 (en) 1998-08-05
CA2198599C (en) 2000-06-06
DE69501620T2 (de) 1998-07-02
TR199501061A2 (tr) 1996-06-21
NO311297B1 (no) 2001-11-12
HUT77310A (hu) 1998-03-30
SK282922B6 (sk) 2003-01-09
MY113733A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9303014A (pt) Composto,composicao farmaceutica,metodo de tratamento de doencas neurolepticas e processo para a preparacao do composto
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9602542A (pt) Composto método para o tratamento de uma doença dependente da fosforilase de glicogénio composição farmacéutica e processo para a preparação de um composto
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9505610A (pt) Composto composição farmacéutica processo para a preparação de um composto uso e método de tratar inflamação e dor
BR9601200A (pt) Composto e seus sais e prodragas farmaceuticamente acetiáveis processo para a preparação de um composto método e composição farmacêutica para o tratamento de doenças hiperproliferativas
PT88200A (pt) Processo para a preparacao de uma composicao para o tratamento da pele
BR9610248A (pt) Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto
BR9506473A (pt) Composto processo para a preparação de compostos utilização de um composto composição farmacêutica e processo para o tratamento de infecções anti-fúngicas
BR9507656A (pt) Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
BR9504791A (pt) Composto polipeptídeo processo para preparação de um composto polipeptídeo composição farmacêutica medicamento e método para tratamento profilático e/ou terapêutico de doenças infecciosas
BR8900357A (pt) Composicao e processo de tratamento de tecido e processo para a preparacao da dita composicao
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
PT101165A (pt) Processo para a preparacao de inibidores duais sem sintese e sem ciclo-oxigenase
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR9707489A (pt) Composto composição farmacêutica e processo para tratar um paciente sofrendo de um distúrbio fisilógico
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
PT96352A (pt) Processo para a preparacao de uma composicao aperfeicoada para tratamento capilar
BR9610733A (pt) Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A.

Free format text: A FIM DE ATENDER AS TRANSFERENCIAS E ALTERACOES DE NOME, REQUERIDAS ATRAVES DA PETICAO NO 20130044258/RJ DE 22/05/2013, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO E O NOME DA EMPRESA QUE CONSTA COMO CEDENTE NA PRIMEIRA TRANSFERENCIA.

B25A Requested transfer of rights approved

Owner name: PFIZER FINANCE INTERNATIONAL LIMITED (IE)

B25A Requested transfer of rights approved

Owner name: PFIZER IRELAND PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: PFIZER OVERSEAS PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: PFIZER IRELAND PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: PFIZER MANUFACTURING IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: PFIZER IRELAND PHARMACEUTICALS (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]